Skip to main content

Table 2 Summary of PK parameters after single (Day 1) and multiple doses (Day 14) of IND/GLY/MF administered via oral inhalation in healthy subjects

From: Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects

 

Japanese

Caucasian

PK parameters (unit)

Profile day

IND/GLY/MF medium-dose N = 15/16

IND/GLY/MF high-dose N = 13/14

IND/GLY/MF medium-dose N = 17

IND/GLY/MF high-dose N = 15

Analyte: indacaterol

 Cmax (pg/mL)

Day 1

388 (25.3)

338 (28.7)

275 (31.8)

282 (33.0)

Day 14

595 (27.2)

593 (27.9)

460 (25.8)

461 (21.1)

 AUC0–24 h (h×pg/mL)

Day 1

1090 (25.0)

1010 (34.5)

862 (25.8)

897 (28.6)

Day 14

3360 (30.3)

3330 (37.1)

2750 (23.0)

2800 (20.3)

 Tmax (h)

Day 1

0.250 (0.250–0.500)

0.250 (0.250–0.250)

0.250 (0.250–0.250)

0.250 (0.250–0.250)

Day 14

0.250 (0.250–0.250)

0.250 (0.250–0.250)

0.250 (0.250–0.250)

0.250 (0.250–0.250)

 Racc (AUC)

Day 14

3.09 (17.8)

3.32 (24.2)

3.31 (25.2)

3.30 (27.8)

 Racc (Cmax)

Day 14

1.57 (20.7)

1.76 (22.1)

1.75 (25.8)

1.74 (27.1)

Analyte: glycopyrronium

 Cmax (pg/mL)

Day 1

318 (53.5)

296 (47.6)

204 (46.2)

215 (48.9)

Day 14

467 (35.1)

464 (42.7)

300 (34.7)

322 (28.9)

 AUC0–24 h (h×pg/mL)

Day 1

294 (25.3)

278 (31.5)

276 (35.2)

280 (33.0)

Day 14

772 (21.0)

751 (17.5)

734 (25.3)

734 (20.7)

 Tmax (h)

Day 1

0.0833 (0.0833–0.0833)

0.0833 (0.0833–0.0833)

0.0833 (0.0833–0.0833)

0.0833 (0.0833–0.0833)

Day 14

0.0833 (0.0833–0.0833)

0.0833 (0.0833–0.0833)

0.0833 (0.0833–0.0833)

0.0833 (0.0833–0.0833)

 Racc (AUC)

Day 14

2.74 (27.5)

2.86 (25.4)

2.84 (30.2)

2.83 (28.4)

 Racc (Cmax)

Day 14

1.69 (41.8)

1.80 (46.3)

1.68 (42.4)

1.90 (65.2)

Analyte: mometasone furoate

 Cmax (pg/mL)

Day 1

105 (16.3)

197 (18.3)

98.6 (22.3)

195 (16.5)

Day 14

141 (18.8)

268 (18.9)

123 (17.9)

252 (14.8)

 AUC0–24 h (h×pg/mL)

Day 1

936 (15.0)

1730 (16.8)

800 (19.9)

1620 (19.2)

Day 14

1270 (15.8)

2540 (14.0)

1040 (16.2)

2220 (12.6)

 Tmax (h)

Day 1

2.00 (0.500–3.00)

1.00 (0.250–2.00)

1.00 (0.250–2.00)

2.00 (0.250–2.00)

Day 14

2.00 (0.250–3.00)

2.00 (0.250–3.00)

1.00 (0.250–3.00)

1.00 (0.250–2.00)

 Racc (AUC)

Day 14

1.37 (14.2)

1.50 (20.1)

1.33 (17.1)

1.40 (12.8)

 Racc (Cmax)

Day 14

1.35 (15.3)

1.38 (18.6)

1.28 (19.8)

1.31 (17.5)

  1. Statistics are arithmetic mean (CV%); for Tmax, statistics are Median (Min–Max). The accumulation ratio (Racc) parameters are derived as the ratio between the profile day shown and the Day 1 results. IND/GLY/MF medium-dose, IND/GLY/MF 150/50/80 μg o.d; IND/GLY/MF high-dose, IND/GLY/MF 150/50/160 μg o.d. AUC, area under curve; Cmax, maximum plasma concentration; IND/GLY/MF, indacaterol/glycopyrronium/mometasone; Racc, accumulation ratios; Tmax, The time to reach the maximum concentration after drug administration. N varies across treatments and ethnicities based on treatment discontinuations during the study as described under study participants. For two Japanese subjects (one profile for the high dose treatment and one profile for the medium dose treatment) for whom pre-dose indacaterol concentration on Day 1 was missing, Day 1 PK parameters were excluded from primary analysis